MNNG/HOS Cl # 5 [R-1059-D] Human Osteosarcoma Cell

This cell line was sampled from a 13-year-old female and was transformed from HOS (ATCC CRL-1543TM) by 0.01mcg/ml MNNG (a carcinogenic nitrosamine). This cell line has high saturation concentration, high cloning rate in soft agar, and can form tumor in nude mice.

Tissue and Cell Type: bone; Osteosarcoma

Culture media and additives/Complete Growth Medium and Culture Conditions:

90% MEM (MD0300)+10% fetal bovine serum (SD0200)+G/A (SD0038)

Complete medium: MEM complete medium (article number: MD0301)

Gas phase: air, 95%; Carbon dioxide, 5%. Temperature: 37 ℃.

Freezing conditions: basic medium+5% DMSO+20% FBS

Complete cryopreservation solution: non-programmed cooling cell cryopreservation solution (low serum) (SD0001)

Note: The product is only for scientific research

PubMed=265298; DOI=10.1002/ijc.2910190411

Rhim J.S., Putman D.L., Arnstein P., Huebner R.J., McAllister R.M.

Characterization of human cells transformed in vitro by N-methyl-N'-nitro-N-nitrosoguanidine.

Int. J. Cancer 19:505-510(1977)

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

PubMed=6254071; DOI=10.1073/pnas.77.9.5258

Todaro G.J., Fryling C., De Larco J.E.

Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors.

Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980)

PubMed=22282976; DOI=10.1093/carcin/1.1.21

Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A., Mattern M.R.

Human tumor cell strains defective in the repair of alkylation damage.

Carcinogenesis 1:21-32(1980)

PubMed=6575958; DOI=10.1007/BF02619599

Tsang K.-Y., Fudenberg H.H., Sun D.C., Pai G.S., Bishop L.R., Sager S.

Cultivation of human osteosarcoma cell lines in serum-free hormone supplemented medium.

In Vitro 19:515-521(1983)

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=2823272; DOI=10.1073/pnas.84.21.7716

Masuda H., Miller C., Koeffler H.P., Battifora H., Cline M.J.

Rearrangement of the p53 gene in human osteogenic sarcomas.

Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=7873286; DOI=10.1016/8756-3282(94)90305-0

Clover J., Gowen M.

Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?

Bone 15:585-591(1994)

PubMed=12645653; DOI=10.1016/S0165-4608(02)00685-4

Ozaki T., Neumann T., Wai D.H., Schaefer K.-L., van Valen F., Lindner N., Scheel C., Bocker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C.

Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.

Cancer Genet. Cytogenet. 140:145-152(2003)

PubMed=19787792; DOI=10.1002/gcc.20717

Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C.

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Genes Chromosomes Cancer 49:40-51(2010)

PubMed=21519327; DOI=10.1038/labinvest.2011.72

Mohseny A.B., Machado I., Cai Y., Schaefer K.-L., Serra M., Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.

Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.

Lab. Invest. 91:1195-1205(2011)

PubMed=24136885; DOI=10.1002/pbc.24801

Guma S.R., Lee D.A., Yu L., Gordon N., Hughes D., Stewart J., Wang W.L., Kleinerman E.S.

Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis.

Pediatr. Blood Cancer 61:618-626(2014)

PubMed=26320182; DOI=10.18632/oncotarget.5177

Ren L., Mendoza A., Zhu J., Briggs J.W., Halsey C., Hong E.S., Burkett S.S., Morrow J., Lizardo M.M., Osborne T., Li S.Q., Luu H.H., Meltzer P.S., Khanna C.

Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.

Oncotarget 6:29469-29481(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29334376; DOI=10.1038/nm.4475

Morrow J.J., Bayles I., Funnell A.P.W., Miller T.E., Saiakhova A., Lizardo M.M., Bartels C.F., Kapteijn M.Y., Hung S., Mendoza A., Dhillon G., Chee D.R., Myers J.T., Allen F., Gambarotti M., Righi A., DiFeo A., Rubin B.P., Huang A.Y., Meltzer P.S., Helman L.J., Picci P., Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Nat. Med. 24:176-185(2018)